A randomised open label trial of favirenz 400 mg + lamivudine 300 mg + tenofovir disoproxil fumarate 300 mg (EFV+3TC+TDF) and bictegravir/emtricitabine/tenofovir alafenamide in people with HIV in China
Latest Information Update: 16 Dec 2022
Price :
$35 *
At a glance
- Drugs Bictegravir/emtricitabine/tenofovir alafenamide (Primary) ; Efavirenz/lamivudine/tenofovir disoproxil fumarate (Primary)
- Indications HIV infections
- Focus Pharmacodynamics
- 16 Dec 2022 New trial record
- 26 Oct 2022 Results presented at the 16th International Congress on Drug Therapy and HIV Infection